within Pharmacolibrary.Drugs.C_CardiovascularSystem.C01C_CardiacStimulantsExclCardiacGlycosides.C01CE04_Bucladesine;

model Bucladesine
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_1C(
    weight = 70,
    F = 1,
    Cl = 4.166666666666667e-06,
    adminDuration = 600,
    adminMass = 100 / 1000000,
    adminCount = 1,
    Vd = 0.02,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Bucladesine</td></tr><tr><td>ATC code:</td><td>C01CE04</td></tr><td>route:</td><td>intravenous</td></tr>
    <tr><td>compartments:</td><td>1</td></tr>
    <tr><td>dosage:</td><td>100</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>20</td><td>L</td></tr>
    <tr><td>clearance:</td><td>15</td><td>L/h</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Bucladesine (dibutyryl cyclic AMP) is a synthetic analog of cyclic adenosine monophosphate (cAMP) that acts as a phosphodiesterase-resistant cAMP derivative. It was investigated for its use as a vasodilator and in the treatment of heart failure and peripheral vascular diseases. It is not currently approved or in clinical use.</p><h4>Pharmacokinetics</h4><p>No human pharmacokinetic parameter data are reported in the literature for bucladesine. The following represents an estimated one-compartment PK model for intravenous administration, reflecting typical parameters for small, hydrophilic nucleoside analogs. These figures are likely to be rough estimates and not derived from primary data.</p><h4>References</h4><ol></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.C.C01CE04 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Bucladesine;
